Modeling and simulation at the interface of nonclinical and early clinical drug development

CPT: Pharmacometrics and Systems Pharmacology

Volumn 2, Issue 2, 2013, Pages

  Visser, S A G ^a,b   Manolis, E ^c   Danhof, M ^d   Kerbusch, T ^e  

^a ASTRAZENECA R AND D   (Sweden)

^b MERCK RESEARCH LABORATORIES   (United States)

^c EUROPEAN MEDICINES AGENCY   (United Kingdom)

^d LEIDEN UNIVERSITY   (Netherlands)

^e NV ORGANON   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ACTIVITY; DOSE CALCULATION; DRUG DEVELOPMENT; DRUG DOSE ESCALATION; DRUG SAFETY; HUMAN; MEDICAL INFORMATION SYSTEM; MODEL; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SIMULATION;

EID: 84881037647     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2013.3     Document Type: Review

References (10)

1. Gabrielsson, J., Dolgos, H., Gillberg, P.G., Bredberg, U., Benthem, B. & Duker, G. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations. Drug Discov. Today 14, 358-372 (2009).
2. Morgan, P. et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov. Today 17, 419-424 (2012).
3. Danhof, M., de Jongh, J., De Lange, E.C., Della Pasqua, O., Ploeger, B.A. & Voskuyl, R.A. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu. Rev. Pharmacol. Toxicol. 47, 357-400 (2007).
4. Sorger, P.K. et al. Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms. NIH White Paper by the QSP Workshop Group (2011).
5. Van der Graaf, P.H. CPT: Pharmacometrics and Systems Pharmacology. CPT Pharmacometrics Syst. Pharmacol. 1, 8 (2012).
6. Berg, J.M., Rogers, M.E. & Lyster, P.M. Systems biology and pharmacology. Clin. Pharmacol. Ther. 88, 17-19 (2010).
7. Lowe, P.J., Hijazi, Y., Luttringer, O., Yin, H., Sarangapani, R. & Howard, D. On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development. Xenobiotica. 37, 1331-1354 (2007). (Pubitemid 350035529)
8. Cohen, A. Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development: designing informative human pharmacology studies. Clin. Pharmacokinet. 47, 373-381 (2008). (Pubitemid 351685387)
9. Manolis, E., Vamvakas, S. & Isaac, M. New pathway for qualification of novel methodologies in the European Medicines Agency. Proteomics. Clin. Appl. 5, 248-255 (2011).
10. Manolis, E. et al. How to use Modeling and Simulation in Clinical Development: Output from the EFPIA/EMA Modeling and Simulation Workshop. CPT Pharmacometrics Syst. Pharmacol. 2, e31 (2013).